0

Close
 
Upcoming Allied Market Research
2023
Immunomodulators Market

Immunomodulators Market

by Product (IMMUNOSUPPRESSANTS, IMMUNOSTIMULANTS) and by Application (Oncology, Respiratory, Human Immunodeficiency Virus (HIV), Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals
Report Code: A03495
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Immunomodulators Market

Request Now !

Immunomodulators are substances that alter the immune response by decreasing the responsiveness of the immune system to make antibodies or sensitized cells. These cells identify and react with the antigen that instigated their production. Some of the immunomodulators are corticosteroids, thymosin, cytotoxic agents, and immunoglobulins. Few of the immunomodulators are naturally present in the body, while some of these are obtained from pharmacological preparations.

The major factors that drive the market growth are increasing usage of monoclonal antibodies to treat diseases such as sclerosis, Crohns disease, rheumatoid arthritis & others, and the rising prevalence of cancer. In addition, availability of effective product pipeline of the companies involved in R&D of immunomodulators further fuels the market growth. However, the presence of stringent regulations involved in the approval procedure for immunomodulator antibodies pose entry difficulties for small-scale manufacturers, less availability of tumor necrosis factor (TNF) inhibitors, and high costs associated with them act as restraints for the market growth. In addition, rising awareness regarding the availability of such immunomodulators is anticipated to provide lucrative growth opportunities for the market.

The report segments the immunomodulators market based on product, application, and region. Based on product, the market is segmented into immunosuppressants and immunostimulants. Based on immunosuppressants, the market is segmented into antibodies, calcineurin inhibitors, glucocorticoids, antimetabolites, and others. Based on immunostimulants, the market is segmented into vaccines, antibodies, and others. Based on application, the market is segmented into oncology, respiratory, human immunodeficiency virus (HIV), and others. Regionally, the market has been analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Benefits

  • The study provides an in-depth analysis of the immunomodulators market, with current trends and future estimations to elucidate imminent investment pockets.
  • It presents a quantitative analysis to enable stakeholders to capitalize on prevailing market opportunities.
  • Extensive analysis of the market by product type elucidates various forms of available immunomodulators.
  • Key players have been profiled and their strategies thoroughly analyzed, which predict the competitive outlook of the market.
  • By region, the market has been analyzed across North America, Europe, Asia-Pacific, and LAMEA.

 Immunomodulators Market Report Highlights

Aspects Details
By Product
  • IMMUNOSUPPRESSANTS
    • Antibodies
    • Calcineurin Inhibitors
    • Glucocorticoids
    • Antimetabolites
    • Others
  • IMMUNOSTIMULANTS
    • Vaccines
    • Antibodies
    • Others
By Application
  • Oncology
  • Respiratory
  • Human Immunodeficiency Virus (HIV)
  • Others
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (Germany, UK, France, Spain, Italy, Rest of Europe)
  • Asia-Pacific  (Japan, China, India, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, Saudi Arabia, South Africa, Argentina, Rest of LAMEA)
Key Market Players F. HOFFMANN-LA ROCHE LTD., JOHNSON & JOHNSON, ABBOTT LABORATORIES, PFIZER INC., AMGEN, INC., NOVARTIS AG, MERCK & CO., INC., BIOGEN INC., BRISTOL-MYERS SQUIBB COMPANY, ELI LILLY AND COMPANY
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: IMMUNOMODULATORS MARKET, BY PRODUCT

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Product

    • 4.2. IMMUNOSUPPRESSANTS

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

      • 4.2.4. Antibodies

        • 4.2.4.1. Market Size and Forecast

      • 4.2.4. Calcineurin Inhibitors

        • 4.2.4.1. Market Size and Forecast

      • 4.2.4. Glucocorticoids

        • 4.2.4.1. Market Size and Forecast

      • 4.2.4. Antimetabolites

        • 4.2.4.1. Market Size and Forecast

      • 4.2.4. Others

        • 4.2.4.1. Market Size and Forecast

    • 4.3. IMMUNOSTIMULANTS

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

      • 4.3.4. Vaccines

        • 4.3.4.1. Market Size and Forecast

      • 4.3.4. Antibodies

        • 4.3.4.1. Market Size and Forecast

      • 4.3.4. Others

        • 4.3.4.1. Market Size and Forecast

  • CHAPTER 5: IMMUNOMODULATORS MARKET, BY APPLICATION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Application

    • 5.2. Oncology

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Respiratory

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Human Immunodeficiency Virus (HIV)

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Others

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

  • CHAPTER 6: IMMUNOMODULATORS MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Product

      • 6.2.3. Market Size and Forecast, By Application

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S. Immunomodulators Market

        • 6.2.5.1. Market Size and Forecast, By Product
        • 6.2.5.2. Market Size and Forecast, By Application

      • 6.2.6. Canada Immunomodulators Market

        • 6.2.6.1. Market Size and Forecast, By Product
        • 6.2.6.2. Market Size and Forecast, By Application

      • 6.2.7. Mexico Immunomodulators Market

        • 6.2.7.1. Market Size and Forecast, By Product
        • 6.2.7.2. Market Size and Forecast, By Application

    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Product

      • 6.3.3. Market Size and Forecast, By Application

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France Immunomodulators Market

        • 6.3.5.1. Market Size and Forecast, By Product
        • 6.3.5.2. Market Size and Forecast, By Application

      • 6.3.6. Germany Immunomodulators Market

        • 6.3.6.1. Market Size and Forecast, By Product
        • 6.3.6.2. Market Size and Forecast, By Application

      • 6.3.7. Italy Immunomodulators Market

        • 6.3.7.1. Market Size and Forecast, By Product
        • 6.3.7.2. Market Size and Forecast, By Application

      • 6.3.8. Spain Immunomodulators Market

        • 6.3.8.1. Market Size and Forecast, By Product
        • 6.3.8.2. Market Size and Forecast, By Application

      • 6.3.9. UK Immunomodulators Market

        • 6.3.9.1. Market Size and Forecast, By Product
        • 6.3.9.2. Market Size and Forecast, By Application

      • 6.3.10. Russia Immunomodulators Market

        • 6.3.10.1. Market Size and Forecast, By Product
        • 6.3.10.2. Market Size and Forecast, By Application

      • 6.3.11. Rest Of Europe Immunomodulators Market

        • 6.3.11.1. Market Size and Forecast, By Product
        • 6.3.11.2. Market Size and Forecast, By Application

    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Product

      • 6.4.3. Market Size and Forecast, By Application

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China Immunomodulators Market

        • 6.4.5.1. Market Size and Forecast, By Product
        • 6.4.5.2. Market Size and Forecast, By Application

      • 6.4.6. Japan Immunomodulators Market

        • 6.4.6.1. Market Size and Forecast, By Product
        • 6.4.6.2. Market Size and Forecast, By Application

      • 6.4.7. India Immunomodulators Market

        • 6.4.7.1. Market Size and Forecast, By Product
        • 6.4.7.2. Market Size and Forecast, By Application

      • 6.4.8. South Korea Immunomodulators Market

        • 6.4.8.1. Market Size and Forecast, By Product
        • 6.4.8.2. Market Size and Forecast, By Application

      • 6.4.9. Australia Immunomodulators Market

        • 6.4.9.1. Market Size and Forecast, By Product
        • 6.4.9.2. Market Size and Forecast, By Application

      • 6.4.10. Thailand Immunomodulators Market

        • 6.4.10.1. Market Size and Forecast, By Product
        • 6.4.10.2. Market Size and Forecast, By Application

      • 6.4.11. Malaysia Immunomodulators Market

        • 6.4.11.1. Market Size and Forecast, By Product
        • 6.4.11.2. Market Size and Forecast, By Application

      • 6.4.12. Indonesia Immunomodulators Market

        • 6.4.12.1. Market Size and Forecast, By Product
        • 6.4.12.2. Market Size and Forecast, By Application

      • 6.4.13. Rest of Asia Pacific Immunomodulators Market

        • 6.4.13.1. Market Size and Forecast, By Product
        • 6.4.13.2. Market Size and Forecast, By Application

    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Product

      • 6.5.3. Market Size and Forecast, By Application

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil Immunomodulators Market

        • 6.5.5.1. Market Size and Forecast, By Product
        • 6.5.5.2. Market Size and Forecast, By Application

      • 6.5.6. South Africa Immunomodulators Market

        • 6.5.6.1. Market Size and Forecast, By Product
        • 6.5.6.2. Market Size and Forecast, By Application

      • 6.5.7. Saudi Arabia Immunomodulators Market

        • 6.5.7.1. Market Size and Forecast, By Product
        • 6.5.7.2. Market Size and Forecast, By Application

      • 6.5.8. UAE Immunomodulators Market

        • 6.5.8.1. Market Size and Forecast, By Product
        • 6.5.8.2. Market Size and Forecast, By Application

      • 6.5.9. Argentina Immunomodulators Market

        • 6.5.9.1. Market Size and Forecast, By Product
        • 6.5.9.2. Market Size and Forecast, By Application

      • 6.5.10. Rest of LAMEA Immunomodulators Market

        • 6.5.10.1. Market Size and Forecast, By Product
        • 6.5.10.2. Market Size and Forecast, By Application

  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning,2022

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. F. HOFFMANN-LA ROCHE LTD.

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. AMGEN, INC.

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. ABBOTT LABORATORIES

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. JOHNSON And JOHNSON

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. NOVARTIS AG

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. BRISTOL-MYERS SQUIBB COMPANY

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. MERCK And CO., INC.

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. ELI LILLY AND COMPANY

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

    • 8.9. PFIZER INC.

      • 8.9.1. Company Overview

      • 8.9.2. Key Executives

      • 8.9.3. Company Snapshot

      • 8.9.4. Operating Business Segments

      • 8.9.5. Product Portfolio

      • 8.9.6. Business Performance

      • 8.9.7. Key Strategic Moves and Developments

    • 8.10. BIOGEN INC.

      • 8.10.1. Company Overview

      • 8.10.2. Key Executives

      • 8.10.3. Company Snapshot

      • 8.10.4. Operating Business Segments

      • 8.10.5. Product Portfolio

      • 8.10.6. Business Performance

      • 8.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL IMMUNOMODULATORS MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL IMMUNOMODULATORS MARKET FOR IMMUNOSUPPRESSANTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL IMMUNOMODULATORS MARKET FOR IMMUNOSTIMULANTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL IMMUNOMODULATORS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL IMMUNOMODULATORS MARKET FOR ONCOLOGY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL IMMUNOMODULATORS MARKET FOR RESPIRATORY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL IMMUNOMODULATORS MARKET FOR HUMAN IMMUNODEFICIENCY VIRUS (HIV), BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL IMMUNOMODULATORS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL IMMUNOMODULATORS MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. NORTH AMERICA IMMUNOMODULATORS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. NORTH AMERICA IMMUNOMODULATORS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 12. NORTH AMERICA IMMUNOMODULATORS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 13. U.S. IMMUNOMODULATORS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 14. U.S. IMMUNOMODULATORS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 15. CANADA IMMUNOMODULATORS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 16. CANADA IMMUNOMODULATORS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 17. MEXICO IMMUNOMODULATORS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 18. MEXICO IMMUNOMODULATORS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 19. EUROPE IMMUNOMODULATORS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 20. EUROPE IMMUNOMODULATORS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 21. EUROPE IMMUNOMODULATORS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 22. FRANCE IMMUNOMODULATORS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 23. FRANCE IMMUNOMODULATORS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 24. GERMANY IMMUNOMODULATORS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 25. GERMANY IMMUNOMODULATORS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 26. ITALY IMMUNOMODULATORS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 27. ITALY IMMUNOMODULATORS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 28. SPAIN IMMUNOMODULATORS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 29. SPAIN IMMUNOMODULATORS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 30. UK IMMUNOMODULATORS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 31. UK IMMUNOMODULATORS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 32. RUSSIA IMMUNOMODULATORS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 33. RUSSIA IMMUNOMODULATORS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 34. REST OF EUROPE IMMUNOMODULATORS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 35. REST OF EUROPE IMMUNOMODULATORS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 36. ASIA-PACIFIC IMMUNOMODULATORS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 37. ASIA-PACIFIC IMMUNOMODULATORS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 38. ASIA-PACIFIC IMMUNOMODULATORS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 39. CHINA IMMUNOMODULATORS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 40. CHINA IMMUNOMODULATORS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 41. JAPAN IMMUNOMODULATORS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 42. JAPAN IMMUNOMODULATORS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 43. INDIA IMMUNOMODULATORS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 44. INDIA IMMUNOMODULATORS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 45. SOUTH KOREA IMMUNOMODULATORS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 46. SOUTH KOREA IMMUNOMODULATORS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 47. AUSTRALIA IMMUNOMODULATORS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 48. AUSTRALIA IMMUNOMODULATORS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 49. THAILAND IMMUNOMODULATORS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 50. THAILAND IMMUNOMODULATORS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 51. MALAYSIA IMMUNOMODULATORS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 52. MALAYSIA IMMUNOMODULATORS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 53. INDONESIA IMMUNOMODULATORS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 54. INDONESIA IMMUNOMODULATORS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 55. REST OF ASIA PACIFIC IMMUNOMODULATORS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 56. REST OF ASIA PACIFIC IMMUNOMODULATORS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 57. LAMEA IMMUNOMODULATORS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 58. LAMEA IMMUNOMODULATORS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 59. LAMEA IMMUNOMODULATORS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 60. BRAZIL IMMUNOMODULATORS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 61. BRAZIL IMMUNOMODULATORS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 62. SOUTH AFRICA IMMUNOMODULATORS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 63. SOUTH AFRICA IMMUNOMODULATORS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 64. SAUDI ARABIA IMMUNOMODULATORS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 65. SAUDI ARABIA IMMUNOMODULATORS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 66. UAE IMMUNOMODULATORS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 67. UAE IMMUNOMODULATORS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 68. ARGENTINA IMMUNOMODULATORS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 69. ARGENTINA IMMUNOMODULATORS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 70. REST OF LAMEA IMMUNOMODULATORS, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 71. REST OF LAMEA IMMUNOMODULATORS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 72. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
  • TABLE 73. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
  • TABLE 74. F. HOFFMANN-LA ROCHE LTD.: OPERATING SEGMENTS
  • TABLE 75. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
  • TABLE 76. F. HOFFMANN-LA ROCHE LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 77. AMGEN, INC.: KEY EXECUTIVES
  • TABLE 78. AMGEN, INC.: COMPANY SNAPSHOT
  • TABLE 79. AMGEN, INC.: OPERATING SEGMENTS
  • TABLE 80. AMGEN, INC.: PRODUCT PORTFOLIO
  • TABLE 81. AMGEN, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 82. ABBOTT LABORATORIES: KEY EXECUTIVES
  • TABLE 83. ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 84. ABBOTT LABORATORIES: OPERATING SEGMENTS
  • TABLE 85. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 86. ABBOTT LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 87. JOHNSON AND JOHNSON: KEY EXECUTIVES
  • TABLE 88. JOHNSON AND JOHNSON: COMPANY SNAPSHOT
  • TABLE 89. JOHNSON AND JOHNSON: OPERATING SEGMENTS
  • TABLE 90. JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
  • TABLE 91. JOHNSON AND JOHNSON: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 92. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 93. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 94. NOVARTIS AG: OPERATING SEGMENTS
  • TABLE 95. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 96. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 97. BRISTOL-MYERS SQUIBB COMPANY: KEY EXECUTIVES
  • TABLE 98. BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
  • TABLE 99. BRISTOL-MYERS SQUIBB COMPANY: OPERATING SEGMENTS
  • TABLE 100. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO
  • TABLE 101. BRISTOL-MYERS SQUIBB COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 102. MERCK AND CO., INC.: KEY EXECUTIVES
  • TABLE 103. MERCK AND CO., INC.: COMPANY SNAPSHOT
  • TABLE 104. MERCK AND CO., INC.: OPERATING SEGMENTS
  • TABLE 105. MERCK AND CO., INC.: PRODUCT PORTFOLIO
  • TABLE 106. MERCK AND CO., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 107. ELI LILLY AND COMPANY: KEY EXECUTIVES
  • TABLE 108. ELI LILLY AND COMPANY: COMPANY SNAPSHOT
  • TABLE 109. ELI LILLY AND COMPANY: OPERATING SEGMENTS
  • TABLE 110. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
  • TABLE 111. ELI LILLY AND COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 112. PFIZER INC.: KEY EXECUTIVES
  • TABLE 113. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 114. PFIZER INC.: OPERATING SEGMENTS
  • TABLE 115. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 116. PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 117. BIOGEN INC.: KEY EXECUTIVES
  • TABLE 118. BIOGEN INC.: COMPANY SNAPSHOT
  • TABLE 119. BIOGEN INC.: OPERATING SEGMENTS
  • TABLE 120. BIOGEN INC.: PRODUCT PORTFOLIO
  • TABLE 121. BIOGEN INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL IMMUNOMODULATORS MARKET SEGMENTATION
  • FIGURE 2. GLOBAL IMMUNOMODULATORS MARKET
  • FIGURE 3. SEGMENTATION IMMUNOMODULATORS MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN IMMUNOMODULATORS MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALIMMUNOMODULATORS MARKET
  • FIGURE 11. IMMUNOMODULATORS MARKET SEGMENTATION, BY BY PRODUCT
  • FIGURE 12. IMMUNOMODULATORS MARKET FOR IMMUNOSUPPRESSANTS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. IMMUNOMODULATORS MARKET FOR IMMUNOSTIMULANTS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. IMMUNOMODULATORS MARKET SEGMENTATION, BY BY APPLICATION
  • FIGURE 15. IMMUNOMODULATORS MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. IMMUNOMODULATORS MARKET FOR RESPIRATORY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. IMMUNOMODULATORS MARKET FOR HUMAN IMMUNODEFICIENCY VIRUS (HIV), BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 18. IMMUNOMODULATORS MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 19. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 20. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 21. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 22. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 23. COMPETITIVE DASHBOARD
  • FIGURE 24. COMPETITIVE HEATMAP: IMMUNOMODULATORS MARKET
  • FIGURE 25. Top player positioning, 2022
  • FIGURE 26. F. HOFFMANN-LA ROCHE LTD.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 27. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 28. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 29. AMGEN, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 30. AMGEN, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 31. AMGEN, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 32. ABBOTT LABORATORIES: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 33. ABBOTT LABORATORIES: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 34. ABBOTT LABORATORIES: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 35. JOHNSON AND JOHNSON: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 36. JOHNSON AND JOHNSON: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 37. JOHNSON AND JOHNSON: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 38. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 39. NOVARTIS AG: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 40. NOVARTIS AG: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 41. BRISTOL-MYERS SQUIBB COMPANY: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 42. BRISTOL-MYERS SQUIBB COMPANY: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 43. BRISTOL-MYERS SQUIBB COMPANY: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 44. MERCK AND CO., INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 45. MERCK AND CO., INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 46. MERCK AND CO., INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 47. ELI LILLY AND COMPANY: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 48. ELI LILLY AND COMPANY: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 49. ELI LILLY AND COMPANY: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 50. PFIZER INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 51. PFIZER INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 52. PFIZER INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 53. BIOGEN INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 54. BIOGEN INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 55. BIOGEN INC.: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now

Purchase Full Report of
Immunomodulators Market

Start reading.
This Report and over 67,404+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers